Bruce Gil
Bruce Gil is a journalist who covers the business and technology sectors. He has reported extensively on pharmaceutical companies and their products, particularly those related to diabetes treatments such as Ozempic and Wegovy. His articles often include interviews with company executives and analysis of financial performance, while also exploring the impact of new technologies on industries. In addition to his work in business journalism, Gil has written about entertainment industry news, including movie box office results and legal disputes within media empires.
Biography:
https://qz.com/author/brucegil
68%
The Daily's Verdict
This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.
Bias
88%
Examples:
- The author has a tendency to favor the companies and products they report on, such as Novo Nordisk and their medications.
- The author often includes statements from company executives without providing evidence or context to support these claims.
Conflicts of Interest
50%
Examples:
- The author frequently reports on the financial performance and decisions of companies without disclosing any potential conflicts of interest.
Contradictions
88%
Examples:
- In one article, the author states that Ozempic is approved for treating type 2 diabetes when it has only been approved for type 1.
- The author contradicts themselves in a few articles by stating that a company or product is facing challenges or declining sales, then later reporting positive news about the same company or product.
Deceptions
62%
Examples:
- The author often reports on studies or developments without providing enough detail or context for readers to fully understand the implications.
- The author uses sensationalism by stating that an artificial pancreas system will improve medical care and quality of life, without providing any evidence to support these claims.
Recent Articles
FDA Approves First Blood Test, Shield, as Primary Screening Option for Colon and Rectal Cancers: A New Convenient Tool to Detect CRC Early
Broke On: Monday, 29 July 2024The FDA approves Guardant Health's Shield blood test as a primary screening option for colorectal cancer in adults over 45, marking the first approval of its kind. With an 83% sensitivity rate and potential accessibility advantages over colonoscopies, the Shield test could encourage more people to get screened for this second deadliest cancer in the US. 
GLP-1 Drug Shortages: Trulicity, Ozempic, and Mounjaro in High Demand for Diabetes Management and Weight Loss
Broke On: Wednesday, 10 July 2024GLP-1 drugs like Ozempic, Trulicity, and Mounjaro experience nationwide shortages due to high demand for their diabetes management and off-label weight loss uses. The FDA and various news sources report patients facing shortages of these medications, with root causes being aggressive marketing campaigns and off-label use. Boston University health economist Rena Conti attributes the issue to these factors. 
Novo Nordisk's Diabetes and Weight Loss Drugs: $600 a Month in the US, $59 in Germany - CEO to Testify Before Senate Committee
Broke On: Monday, 17 June 2024Novo Nordisk, Europe's most valuable company in 2023, faces scrutiny over price discrepancies of diabetes drugs Ozempic and Wegovy in the US. The CEO will testify before the Senate HELP committee regarding these high prices, which are significantly lower in other countries. A study found that Ozempic costs $541 less per month in Germany, while Wegovy costs $727 less in the UK. Critics argue that justifications for these price disparities do not excuse such significant differences. 
Moderna in Talks with US Government for Funding of Potential Bird Flu Vaccine, mRNA-1018
Broke On: Tuesday, 28 May 2024Moderna is in talks with the U.S. government for potential funding and a purchase commitment for its mRNA H5N1 bird flu vaccine, mRNA-1018, following confirmation of human cases in the US. The rapid spread of H5N1 among poultry and cattle necessitates quick production through mRNA technology, with Moderna expecting data soon from early-stage trials. Moderna in Talks with US Government for Funding of Potential Bird Flu Vaccine, mRNA-1018
Broke On: Tuesday, 28 May 2024Moderna is in talks with the U.S. government for potential funding and a purchase commitment for its mRNA H5N1 bird flu vaccine, mRNA-1018, following confirmation of human cases in the US. The rapid spread of H5N1 among poultry and cattle necessitates quick production through mRNA technology, with Moderna expecting data soon from early-stage trials. 
New FAA Rest Requirements for Air Traffic Controllers: 10 Hours Off Between Shifts and 12 Hours Before Midnight Shift
Broke On: Friday, 19 April 2024The FAA implements new rest requirements for air traffic controllers, mandating a minimum of 10 hours off between shifts and 12 hours off before midnight shifts, in response to concerns over fatigue and safety issues. The changes aim to address risks associated with controller fatigue and reverse decades-long staff shortages. Hiring 1,800 new controllers this year is part of the FAA's efforts to improve working conditions and prioritize controller safety. 
WHO Updates Terminology: Pathogens That Transmit Through the Air - COVID-19, Influenza, and More
Broke On: Thursday, 18 April 2024The World Health Organization (WHO) has updated the terminology for airborne viruses, including COVID-19, to be called 'pathogens that transmit through the air.' The WHO now discourages differentiating between aerosols and larger droplets and emphasizes they exist on a continuous spectrum of sizes. This update aims to eliminate confusion in communicating virus transmission among human populations following discrepancies during the COVID-19 pandemic response. 
Revolutionizing Type 1 Diabetes: The NHS Rolls Out Artificial Pancreas System
Broke On: Thursday, 04 April 2024The NHS in England is set to roll out an artificial pancreas system, also known as a closed loop system, to people with Type 1 diabetes. The hybrid closed loop system will continually monitor a person's blood glucose levels and automatically adjust the amount of insulin given through a pump. This technology holds the power to redefine the lives of those with Type 1 diabetes by promising better quality of life as well as clinical outcomes. 
Wegovy Now Covered Under Medicare Part D for Heart Health in Obese and Overweight Adults
Broke On: Thursday, 21 March 2024Medicare Part D covers Wegovy, a weight loss drug that reduces heart risks for obese or overweight adults. The FDA approved it in March after a clinical trial showed 20% reduction in serious heart events. 
Diamondback Energy and Endeavor Energy Resources Announce $26 Billion Merger in Permian Basin Oil and Gas Industry
Broke On: Monday, 12 February 2024The Permian Basin, straddling New Mexico and Texas, is the most productive oil and gas field in the US. Diamondback Energy generates $9.6 billion in revenue from oil while Endeavor Energy Resources based out of Midland joins forces with Diamondback through a $26 billion merger deal.